The biofilm inhibitor Carolacton inhibits planktonic growth of virulent pneumococci via a conserved target
Data(s) |
2016
|
---|---|
Resumo |
New antibacterial compounds, preferentially exploiting novel cellular targets, are urgently needed to fight the increasing resistance of pathogens against conventional antibiotics. Here we demonstrate that Carolacton, a myxobacterial secondary metabolite previously shown to damage Streptococcus mutans biofilms, inhibits planktonic growth of Streptococcus pneumoniae TIGR4 and multidrug-resistant clinical isolates of serotype 19A at nanomolar concentrations. A Carolacton diastereomer is inactive in both streptococci, indicating a highly specific interaction with a conserved cellular target. S. mutans requires the eukaryotic-like serine/threonine protein kinase PknB and the cysteine metabolism regulator CysR for susceptibility to Carolacton, whereas their homologues are not needed in S. pneumoniae, suggesting a specific function for S. mutans biofilms only. A bactericidal effect of Carolacton was observed for S. pneumoniae TIGR4, with a reduction of cell numbers by 3 log units. The clinical pneumonia isolate Sp49 showed immediate growth arrest and cell lysis, suggesting a bacteriolytic effect of Carolacton. Carolacton treatment caused a reduction in membrane potential, but not membrane integrity, and transcriptome analysis revealed compensatory reactions of the cell. Our data show that Carolacton might have potential for treating pneumococcal infections. |
Identificador | |
Idioma(s) |
eng |
Publicador |
London : Macmillan Publishers Limited |
Relação |
http://dx.doi.org/10.1038/srep29677 ISSN:2045-2322 ESSN:2045-2322 |
Direitos |
CC-BY 4.0 https://creativecommons.org/licenses/by/4.0/ frei zugänglich |
Fonte |
Scientific reports 6 (2016) |
Palavras-Chave | #Carolacton #S. pneumoniae TIGR4 #Medical Microbiology #Infection Research #ddc:500 |
Tipo |
status-type:publishedVersion doc-type:article doc-type:Text |